Skip to main content

Advertisement

Log in

Clinical characteristics and long-term outcome of patients with POEMS syndrome in China

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

POEMS syndrome is a rare plasma cell dyscrasia characterized by polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes. This study reviewed the clinical characteristics and long-term outcome of 99 consecutive Chinese patients with newly diagnosed POEMS syndrome in a single institute. The median age of 99 patients was 45 years, and the ratio of men/women was 1.4. The median time from onset of symptoms to diagnosis was 18 months. The typical five features of peripheral neuropathy, organomegaly, endocrinopathy, M protein, and skin change remained to be essential for patients with POEMS syndrome in China. The unusual features like pulmonary hypertension (36%) and renal impairment (37%) were not uncommon in China. Eighty-three percent patients were alive after follow-up time of 25 months, and 10% patients had survived more than 60 months. Melphalan-based therapy (OR, 0.076; 95% CI, 0.02–0.285) and normal renal function (OR, 0.246; 95% CI, 0.076–0.802) were independent prognostic factors for the survival of patients with POEMS syndrome. In conclusion, POEMS syndrome in Chinese patients was a multi-systemic disease with clinical features similar to non-Chinese ones. Active therapy can effectively improve the prognosis of patients with POEMS syndrome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Dispenzieri A (2007) POEMS syndrome. Blood Rev 21:285–299

    Article  PubMed  Google Scholar 

  2. Watanabe O, Arimura K, Kitajima I et al (1996) Greatly raised vascular endothelial growth factor (VEGF) in POEMS syndrome. Lancet 347:702

    Article  PubMed  CAS  Google Scholar 

  3. Nakanishi T, Sobue I, Toyokura Y et al (1984) The Crow–Fukase syndrome: a study of 102 cases in Japan. Neurology 34:712–720

    PubMed  CAS  Google Scholar 

  4. Dispenzieri A, Kyle RA, Lacy MQ et al (2003) POEMS syndrome: definitions and long-term outcome. Blood 101:2496–2506

    Article  PubMed  CAS  Google Scholar 

  5. Zhu WG, Wang Y, Zeng XJ et al (2006) A clinical analysis of 32 cases of POEMS syndrome. Zhonghua Nei Ke Za Zhi 45:108–111

    PubMed  Google Scholar 

  6. Zhang B, Song X, Liang B et al (2010) The clinical study of POEMS syndrome in China. Neuro Endocrinol Lett 31:229–237

    PubMed  Google Scholar 

  7. Cui R, Huang X, Shi Q et al (2010) POEMS syndrome in China. Intern Med J. doi:10.1111/j.1445-5994.2010.02172.x

  8. Dupont SA, Dispenzieri A, Mauermann ML et al (2009) Cerebral infarction in POEMS syndrome: incidence, risk factors, and imaging characteristics. Neurology 73:1308–1312

    Article  PubMed  CAS  Google Scholar 

  9. Soubrier MJ, Dubost JJ, Sauvezie BJ (1994) POEMS syndrome: a study of 25 cases and a review of the literature. French Study Group on POEMS Syndrome. Am J Med 97:543–553

    Article  PubMed  CAS  Google Scholar 

  10. Donaghy M, Hall P, Gawler J et al (1989) Peripheral neuropathy associated with Castleman’s disease. J Neurol Sci 89:253–267

    Article  PubMed  CAS  Google Scholar 

  11. Allam JS, Kennedy CC, Aksamit TR et al (2008) Pulmonary manifestations in patients with POEMS syndrome: a retrospective review of 137 patients. Chest 133:969–974

    Article  PubMed  Google Scholar 

  12. Jouve P, Humbert M, Chauveheid MP et al (2007) POEMS syndrome-related pulmonary hypertension is steroid-responsive. Respir Med 101:353–355

    Article  PubMed  Google Scholar 

  13. Nakamoto Y, Imai H, Yasuda T et al (1999) A spectrum of clinicopathological features of nephropathy associated with POEMS syndrome. Nephrol Dial Transplant 14:2370–2378

    Article  PubMed  CAS  Google Scholar 

  14. Sano M, Terasaki T, Koyama A et al (1986) Glomerular lesions associated with the Crow–Fukase syndrome. Virchows Arch A Pathol Anat Histopathol 409:3–9

    Article  PubMed  CAS  Google Scholar 

  15. Kuwabara S, Dispenzieri A, Arimura K et al (2008) Treatment for POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome. Cochrane Database Syst Rev (4):CD006828

  16. Kuwabara S, Hattori T, Shimoe Y et al (1997) Long term melphalan-prednisolone chemotherapy for POEMS syndrome. J Neurol Neurosurg Psychiatry 63:385–387

    Article  PubMed  CAS  Google Scholar 

  17. Dispenzieri A, Moreno-Aspitia A, Suarez GA et al (2004) Peripheral blood stem cell transplantation in 16 patients with POEMS syndrome, and a review of the literature. Blood 104:3400–3407

    Article  PubMed  CAS  Google Scholar 

  18. Palladini G, Perfetti V, Obici L et al (2004) Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 103:2936–2938

    Article  PubMed  CAS  Google Scholar 

  19. Comenzo RL (2009) How I treat amyloidosis. Blood 114:3147–3157

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Dao-Bin Zhou.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Li, J., Zhou, DB., Huang, Z. et al. Clinical characteristics and long-term outcome of patients with POEMS syndrome in China. Ann Hematol 90, 819–826 (2011). https://doi.org/10.1007/s00277-010-1149-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-010-1149-0

Keywords

Navigation